"An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) " - Regional Cancer Care Associates LLC

Clinical Trials

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung
Locations
Hackensack
Sponsor
Bristol-Myers Squibb
Protocol Number
CA209-568
Cancer Diagnosis
To Learn More Call
201-510-0910